A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non-small Cell Lung Cancer.
Edward B GaronAlexander I SpiraMelissa JohnsonLyudmila BazhenovaJoseph LeachAmy L CummingsAlbert CandiaRobert L CoffmanMary J JanatpourRobert JanssenErick GamelinLaura Q M ChowPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
DV281 with nivolumab was well tolerated with target engagement observed at every dose. Pharmacodynamic advantages at doses above 10 mg were unclear. The long duration of disease control in 50% of patients suggests clinically relevant activity in this population of heavily pretreated patients.